Get the Stockscreener App
8.18
2.25%
0.18
Engene Holdings Inc stock is traded at $8.18, with a volume of 164.39K.
It is up +2.25% in the last 24 hours and up +25.27% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$8.00
Open:
$8
24h Volume:
164.39K
Relative Volume:
0.13
Market Cap:
$547.02M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-1.7782
EPS:
-4.6001
Net Cash Flow:
$-26.70M
1W Performance:
-0.85%
1M Performance:
+25.27%
6M Performance:
+113.58%
1Y Performance:
-4.55%
1-Day Range:
$7.96
$8.22
1-Week Range:
$7.5519
$8.355
52-Week Range:
$2.65
$11.14
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
8.18 | 534.98M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial - Finviz
How enGene Holdings Inc. stock performs in rate cut cyclesJuly 2025 Rallies & Long Hold Capital Preservation Plans - Newser
H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Engene stock as detalimogene joins FDA pilot program - Investing.com Nigeria
Franklin Resources Inc. Sells 136,866 Shares of enGene Holdings Inc. $ENGN - MarketBeat
9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey
FDA selects enGene’s bladder cancer therapy for development program By Investing.com - Investing.com Australia
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readines - pharmiweb.com
enGene stock rises after FDA selects bladder cancer therapy for CMC pilot program - Investing.com Nigeria
Engene's detalimogene selected for FDA manufacturing pilot program to support manufacturing readiness - MarketScreener
enGene’s Detalimogene Chosen for FDA Manufacturing Pilot Program - TipRanks
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness - Markets Financial Content
What valuation multiples suggest for enGene Holdings Inc. Equity Warrant stockEarnings Performance Report & Risk Managed Investment Entry Signals - Newser
Can enGene Holdings Inc. Equity Warrant stock attract ESG capital inflowsForecast Cut & AI Optimized Trading Strategy Guides - moha.gov.vn
enGene Holdings Inc Stock Analysis and ForecastHealthcare Stock Analysis & Learn the Secrets of Pro Traders - earlytimes.in
enGene (NASDAQ:ENGN) Trading Up 6.9%Should You Buy? - MarketBeat
enGene Holdings Prices $130 Million Public Offering to Advance Genetic Medicine Programs - MSN
enGene to Present at Piper Sandler Healthcare Conference - TipRanks
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference - Markets Financial Content
PERCEPTIVE ADVISORS LLC's Strategic Acquisition in enGene Holdings Inc. - GuruFocus
What drives enGene Holdings Inc Equity Warrant stock priceDebt-to-Equity Ratio Analysis & High Return Trading Ideas - earlytimes.in
enGene Holdings Inc. (ENGN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is enGene Holdings Inc. stock a dividend growth opportunityBuy Signal & Momentum Based Trading Ideas - newser.com
How enGene Holdings Inc. Equity Warrant stock reacts to inflationary pressuresTrade Performance Summary & Growth Focused Entry Point Reports - newser.com
How enGene Holdings Inc. stock compares to growth peersGap Down & Stock Timing and Entry Methods - newser.com
enGene Holdings Inc. (S0N.F) stock price, news, quote and history - Yahoo Finance UK
Is a relief rally coming for enGene Holdings Inc. holders2025 Institutional Moves & Weekly High Return Stock Forecasts - newser.com
Is enGene Holdings Inc. Equity Warrant trending in predictive chart modelsPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Is enGene Holdings Inc. Equity Warrant stock bottoming out2025 Top Decliners & Daily Entry Point Alerts - newser.com
Multi asset correlation models including enGene Holdings Inc. Equity WarrantWeekly Trade Recap & Verified Momentum Watchlists - newser.com
How institutional buying supports enGene Holdings Inc. stockQuarterly Investment Review & Safe Entry Trade Reports - newser.com
ENGN: Non-viral gene therapy for NMIBC achieves 62% six-month CR rate, targeting 2027 approval - TradingView
Is enGene Holdings Inc. Equity Warrant stock undervalued vs historical averages2025 Price Targets & Weekly High Return Opportunities - newser.com
enGene Holdings (ENGN) Price Target Increased by 10.59% to 24.20 - Nasdaq
Will enGene Holdings Inc. stock reach all time highs in 2025July 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Has enGene Holdings Inc. Equity Warrant found a price floorSwing Trade & Community Verified Trade Alerts - newser.com
Why enGene Holdings Inc. stock is favored by top institutions2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):